Gistinfo

• CML Alliance Blood Level Testing: Click Here
• List of GIST Doctors: Click Here
• GCRF featured in PitMed Magazine, See page 34: A Check that came with a Kiss.
• Cristina Antonescu from MSKCC Memorial Sloan-Kettering Cancer Center: The Researcher Perspective
• GIST Research Projects in the Heinrich & Corless Laboratories: Synopsis of Projects

Clinical Trials/Medical Resources:

• Pfizer Oncology’s FIRSTresource program, can help defray the cost of accessing the newly approved drug, SUTENT. Direct phone number to Pfizer’s FirstResource Program, call 1-877-744-5675.
• Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure
• Novartis GLEEVEC Reimbursement hotline: Click Here – 1-877-453-3832
• Nexavar REACH Insurance Coverage and Assistance: Click Here
• Benefits Checkup: National Council on Aging provides information on assistance programs: Click Here
• PSI: A non-profit organization for patient assistance: Click Here
• HealthWell Foundation: A non-profit organization for patient assistance: Click Here
• IPI-504 clinical trial (ClinicalTrials.gov: NCT00688766): Click Here, and Here for more Info
• Clinical Trial List Site (check regularly): Click Here
• Possible Optimization of GIST patient treatments in research study: Click Here
• The Lessons of GIST: PET and PET/CT – A New Paradigm for Imaging
• Research from MSKCC in NY: Immunotherapy Research
• Research from Fax Chase Cancer Center: Link
• A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up.
• An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)
• A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
• Infinity Pharmaceuticals Initiates Phase I Clinical Trial of IPI-504 for Patients with Gastrointestinal Stromal Tumors (GIST).
• Glivec International Patient Assistance Program (GIPAP) can help defray the cost of Gleevec.
• Novartis (Gleevec) Patient Assistance Program also helps with the cost of obtaining Gleevec. 1-866-884-5906
• AMN107, under development by Novartis, which also makes Gleevec, is one of two “son of Gleevec” agents being pursued to treat patients who are refractory to Gleevec or who develop resistance.
• 
  Help Novartis Oncology collect information from doctors on the diagnosis and management of GIST via doctor participation in a GIST registry. A copy of a brochure about the GIST registry is available for you to print and then bring to your doctor by clicking here.
• ASCO’s information for people living with cancer. [Link]
• Just been diagnosed with a rare form of cancer?  Please visit www.rarecancerconnection.com

Patient Resources from Pfizer Oncology Nurse Video Q&A About SUTENT for the Treatment of Imatinib-Resistant or -Intolerant GIST Click Here Symptom and Side Effect Guide  Click Here GIST Question Builder for Doctor’s Visits  Click Here Reimbursement Support Services from First Resource Click Here SUTENT Patient Call Center  Click Here Get a  “Treatment Partner” Click Here Tips for Living with GIST Click Here Build a SUTENT Calendar Click Here Build a Treatment Team Contact List  Click Here Build a Prescription Tracker Click Here Build a Resource Guide Click Here

Additional Education/Research Resources:

• National Cancer Institute statement on GLEEVEC: Click Here
• Index of publications from Heinrich-Corless Laboratory in 2008: Click Here
• Differences in GIST after TKI therapy: Click Here
• NCCN Task Force Report: Optimal Management of Patients with Gastrointestinal Stromal Tumor (GIST)Update of the NCCN Clinical Practice Guidelines (July, 2007)
• Surgery of residual disease following Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST) – Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings
• Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST) – Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
• Perioperative morbidity in metastatic gastrointestinal stromal tumors (GIST) undergoing surgery of residual disease following imatinib (IM) – Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings
• Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors – Journal of Clinical Oncology 2006
• Liver Cancer – The most common cancer worldwide: Click Here
• GIST Comes of Age: Current Management Using Molecular Pathology, Surgery, and Targeted Therapy: Click Here
• Information on GIST: Gastrointestinal Stromal Tumor
• As of 2008, Pfizer has a new grant management system for reviewing and supporting independent professional education activities.  All requests for support for CME programs must be submitted directly to Medical Education Grants (MEG) via the website www.pfizermededgrants.com.
• Archive: Kinasedx.com GIST Information Resource Page and Presentation
• Heinrich-Corless Laboratory
• ASCO 2006 Presentation: Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate therapy in a phase III trial, 2006. [ASCO Website]
• ASCO 2006 Presentation: Outcome of advanced GIST patients treated with imatinib mesylate: four-year follow-up of a randomized Phase II trial [ASCO Website}
• Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
• ASCO 2005 Presentation: Outcome of Advanced Gastrointestinal Stromal Tumor (GIST) Patients Treated With Imatinib Mesylate: Four- Year Follow-Up of a Phase II Randomized Trial.
  Presentation Slides